0R2S Stock Chart & Stats
$351.49
-$0.57(-0.16%)
At close: 4:00 PM EDT
$351.49
-$0.57(-0.16%)
Day’s Range― - ―
52-Week Range$281.04 - $396.86
Previous CloseN/A
Volume11.00
Average Volume (3M)3.49K
Market Cap
$126.81B
Enterprise Value$133.50K
Total Cash (Recent Filing)$3.48B
Total Debt (Recent Filing)$14.94B
Price to Earnings (P/E)33.9
Beta0.71
Next Earnings
Oct 29, 2026EPS Estimate
3.58Next Dividend Ex-DateN/A
Dividend Yield1.05%
Share Statistics
EPS (TTM)9.73
Shares Outstanding383,573,060
10 Day Avg. Volume934
30 Day Avg. Volume3,490
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$384.82Price Target Upside9.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)15.02
Revenue Forecast (FY)$27.30B
Bulls Say, Bears Say
Bulls Say
Broad Organic Growth And Margin ExpansionBroad growth across regions and segments, combined with expanding gross and operating margins, indicates durable demand and operating leverage. This supports continued earnings growth if procedure volumes and hospital spending remain healthy.
Strong Free Cash Flow And Improving LeverageHigh free-cash-flow conversion provides funding for innovation, acquisitions, debt reduction and shareholder returns. Deleveraging from prior periods also improves financial flexibility and reduces balance-sheet risk over the medium term.
Innovation And Expanding Technology PortfolioA steady cadence of product launches and rising Mako utilization strengthens Stryker’s technology offering and supports procedure-based recurring demand. AVS adds intravascular lithotripsy capability, broadening future growth opportunities.
Bears Say
Peripheral Vascular Supply DisruptionThe disruption exposes execution and supply-chain concentration risk in a growth category, with lost sales and backorders affecting results. Although management expects improvement by the end of Q3, recovery depends on restoring reliable production.
Ongoing Cybersecurity Remediation CostsResidual cybersecurity costs can weigh on earnings and cash generation beyond the initial disruption while management allocates resources to remediation. Continued spending also indicates operational resilience and infrastructure remain areas of risk.
Meaningful Debt And Uneven Cash ConversionLeverage has improved, but sizable absolute debt limits flexibility if acquisition activity or financing costs rise. Operating cash flow below EBITDA also shows that working capital and cash-cost timing can periodically weaken the quality of earnings conversion.
Stryker News
0R2S FAQ
What was Stryker Corporation’s price range in the past 12 months?
Stryker Corporation lowest share price was $281.04 and its highest was $396.86 in the past 12 months.
What is Stryker Corporation’s market cap?
Stryker Corporation’s market cap is $126.81B.
When is Stryker Corporation’s upcoming earnings report date?
Stryker Corporation’s upcoming earnings report date is Oct 29, 2026 which is in 63 days.
How were Stryker Corporation’s earnings last quarter?
Stryker Corporation released its earnings results on Jul 30, 2026. The company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.488 by $0.202.
Is Stryker Corporation overvalued?
According to Wall Street analysts Stryker Corporation’s price is currently Undervalued.
Does Stryker Corporation pay dividends?
Stryker Corporation pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 1.05%. See more information on Stryker Corporation dividends here
What is Stryker Corporation’s EPS estimate?
Stryker Corporation’s EPS estimate is 3.58.
How many shares outstanding does Stryker Corporation have?
Stryker Corporation has 383,573,060 shares outstanding.
What happened to Stryker Corporation’s price movement after its last earnings report?
Stryker Corporation reported an EPS of $3.69 in its last earnings report, beating expectations of $3.488. Following the earnings report the stock price went down -6.568%.
Which hedge fund is a major shareholder of Stryker Corporation?
Currently, no hedge funds are holding shares in GB:0R2S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$384.82 (9.48% Upside)
$384.82 (9.48% Upside)
Blogger Sentiment
Bullish
GB:0R2S Sentiment 73%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $215.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.89%
12-Months-Change
Fundamentals
Return on Equity
1.05%
Trailing 12-Months
Asset Growth
3.45%
Trailing 12-Months
Company Description
Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
0R2S Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad recovery and operational momentum: solid organic growth (9%), a strong adjusted EPS beat (+17.9%), expanding margins, record Mako performance, multiple product launches and healthy cash generation/backlog. Key negatives were an acute supply disruption in peripheral vascular (Inari) that drove a U.S. vascular decline (‑6.7%), lingering costs and absorption effects from the prior cybersecurity incident, and some launch timing variability. Management expects backorders to be manageable by end of Q3 and reiterated confidence in the full‑year outlook and capital demand, so positives materially outweigh manageable near‑term headwinds.View all GB:0R2S earnings summaries0R2S Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine

0R2S Stock 12 Month Forecast
Average Price Target
$384.82
▲(9.48% Upside)
Technical Analysis
Integra Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―
Globus Medical
―











